PharmaEssentia Names Eric Vogel as U.S. Commercialization Head in Preparation for Potential BESREMi® Launch in Essential Thrombocythemia PharmaEssentia Corporation has announced the appointment of Eric Vogel as the company’s new U.S. Head of Commercialization, strengthening its leadership team as it…
Daiichi Sankyo Europe Highlights Broad EAS Congress 2026 Data Presentations Supporting Patient-Centred Cardiovascular Care Daiichi Sankyo Europe has announced a major scientific presence at the upcoming European Atherosclerosis Society Congress 2026, highlighting the company’s continued commitment to advancing cardiovascular care…
Arrowhead Pharmaceuticals Unveils Encouraging Clinical Cardiometabolic Findings at the 94th European Atherosclerosis Society Congress Arrowhead Pharmaceuticals has presented new clinical findings supporting the broader use of plozasiran, its investigational small interfering RNA therapy targeting apolipoprotein C-III (APOC3), during two oral…
LIB Therapeutics Highlights New Clinical Findings on LEROCHOL Presented at the 2026 European Atherosclerosis Society Congress in Athens LIB Therapeutics has reported new long-term clinical data for LEROCHOL® (lerodalcibep-liga), its recently approved third-generation PCSK9 inhibitor, during presentations at the European…
Agilent Technologies Introduces Advanced Multi-Attribute Method Solution to Streamline BioPharma Quality Control and Analytical Testing Agilent Technologies has announced the launch of a new multi-attribute method (MAM) workflow designed to help pharmaceutical and biopharmaceutical quality control laboratories adopt liquid chromatography…
Curi Bio Unveils Curiverse™ at MPS 2026, the First Closed-Loop Platform for Human-Relevant Drug Discovery Curi Bio has officially unveiled the Curiverse™ at the Microphysiological Systems World Summit 2026, introducing what the company describes as the industry’s first fully integrated…
BreezeBio Establishes Scientific Advisory Board to Advance Precision Genetic Medicine Pipeline BreezeBio, formerly known as GenEdit, has announced the formation of its inaugural Scientific Advisory Board (SAB), marking a significant step in the company’s ongoing expansion as it advances a…
Verastem Oncology Names Michael P. Bailey to Board of Directors Verastem Oncology has announced the appointment of veteran biotechnology executive Michael P. Bailey to its Board of Directors, strengthening the company’s leadership team as it advances a growing portfolio of…
Agios Secures EU Approval for PYRUKYND® (mitapivat) to Treat Adults Living with Thalassaemia, Announces Avanzanite Bioscience Avanzanite Bioscience B.V. has announced a major milestone in the treatment of rare blood disorders following the European Commission’s approval of PYRUKYND® (mitapivat) for…
Enhertu® Receives CHMP Recommendation for EU Approval in HER2-Positive Metastatic Solid Tumors Enhertu has received a positive recommendation for approval in the European Union from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency for…
Merck Secures CHMP Support for KEYTRUDA® Plus Padcev® in Muscle-Invasive Bladder Cancer Merck, known as MSD outside the United States and Canada, has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has…
Gilead Wins CHMP Backing for Trodelvy® in First-Line Metastatic TNBC Treatment Gilead Sciences has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion recommending the approval of Trodelvy…